AMR Sept Banner v2

ASM Attends UN General Assembly

ASM President, Susan Sharp, Ph.D., joined global leaders at the United Nations General Assembly in New York today in a historical meeting to focus on the commitment to fight AMR.
Read

UN General Assembly Focuses on AMR

Leaders at the UN General Assembly draft a plan for coordinated, cross-cutting efforts to improve the current state of AMR.
Read

Superbugs are a 'Fundamental Threat'

If antibiotics were telephones, we would still be calling each other using clunky rotary dials and copper lines," Stefano Bertuzzi, CEO of ASM, told NBC News.
Read
Become a member today!
JOIN ASM
Submit Abstracts for Biothreats 2017
SUBMIT
Antibacterial Development Conference
REGISTER

frank dara

 

The research program in the Frank lab centers on the pathogenesis of two Gram-negative bacteria, Pseudomonas aeruginosa and Francisella tularensis. P. aeruginosa is a bacterium that is an inhabitant of soil and water. Normal individuals are generally not susceptible to P. aeruginosa-mediated infections, however, several underlying conditions or traumas increase the risk for an acute episode. These conditions include extensive burns, eye trauma, mechanical ventilation, HIV infection, neutropenia or malignancy. Cystic fibrosis (CF) patients often suffer from life-long chronic colonization by P. aeruginosa. The constant presence of bacterial antigens coupled with intense inflammatory responses contributes to diminution of lung function and quality of life. Regardless of the type of infection, antimicrobial treatment is complicated by a notable intrinsic resistance and emergence of multi-drug resistant strains. Dr. Frank's lab was instrumental in the initial discovery and characterization of the P. aeruginosa type III system. Her laboratory continues the study of this system and the toxins that are injected into eukaryotic cells. Major research goals of the program include the development of specific enzyme inhibitors, antibody reagents or vaccines that neutralize the tissue-damaging toxins that P. aeruginosa synthesize. She has a single chain antibody therapeutic currently in clinical trials and is continuing to study the mechanistic features and biological outcomes of type III-mediated delivery of toxins. Francisella tularensis is the etiologic agent that causes tularemia in humans and animals. The organism poses a serious threat as only a few bacteria (10-50 colony forming units) are necessary to avoid innate immunity and rapidly replicate in the lymphoid tissues of human hosts. As part of the national biodefense program, the Frank lab in collaboration with Dr. Thomas C. Zahrt developed research strategies to understand the pathogenesis of F. tularensis using genetic approaches. The goals of this project are to identify virulence factors as potential targets for therapeutic or vaccine development and to understand how these factors work in concert to overcome the host innate defenses.

TPL_asm2013_SEARCH

91022